陈建伟

2014.08年-2016.09年，受国家留学基金委资助在美国罗德岛大学联合培养，2016年12月获浙江工业大学药物化学专业博士学位，后在浙江工业大学从事师资博士后研究。2019年05月加入浙江工业大学药学院，现任副研究员、硕士生导师。主要从事海洋微生物来源抗菌先导化合物的研究，以第一作者或通讯作者在Pharmeuctial Research、Drug Discovery Today、European Journal of Medicinal Chemistry、Organic Letters、Journal of Natural Products等期刊发表SCI论文20余篇，参与发表SCI论文共计50余篇，论文共被引642次，h-引用因子12。获授权专利5件，公开PCT专利1件，申请美国专利1件。先后主持国家重点研发计划子课题2项，国家自然科学基金应急管理项目1项，浙江省重点研发计划课题1项，浙江省自然科学基金1项、博士后科学基金1项（一等），参与国家重点研发项目政府间合作专项1项，国家重点研发计划子课题1项，国家自然科学基金面上项目2项以及多项横向科研项目。2019年入选国家“澳门青年学者计划”支持。

主讲本科生《海洋药物学》，《天然药物化学》，《天然药物化学B》

(1) 国家科技部，国家重点研发计划子课题，2022YFC2804205，深海候选药物活性分子成药性潜力评估，2023-01 至 2026-12, 在研，主持

(2) 浙江省自然科学基金委，公益项目，GF21H300010，两株深海细菌中新型抗菌先导化合物的挖掘及对耐药性铜绿假单胞菌治疗的研究，2021-01 至 2023-12, 在研，主持

(3) 浙江省科技厅，重点研发计划课题，2021C03084，候选药物开发研究-一种抗细菌耐药性新型抗生素候选药物的开发研究，2021.01 至 2023.12，在研，主持

(4) 国家自然科学基金委员会, 应急管理项目, 81741165, 基于Genome Shuffling技术的深海来源重组微生物中群体感应抑制剂的 挖掘及作用机制研究，2018-01-01 至 2018-12-31，结题，主持

(5) 国家科技部，国家重点研发计划子课题，2018YFC0311003，高通量新靶点抗细菌、癌症耐药先导化合物的筛选与评价2018-08 至 2021-12, 结题, 主持

(6) 国家自然科学基金委员会，面上项目，41776139，基于OSMAC方法探索滨海植物来源共生曲霉菌D的化学多样性研究, 2018-01-01 至 2021-12-31，结题，参与

(7) 国家自然科学基金委员会，面上项目，81773628, 深海来源微生物中Siderophore类化合物的发掘及生物合成研究, 2018-01-01 至 2021-12-31，结题，参与

(8) 国家科技部, 重点研发计划项目（政府间重点专项），2017YFE0103100, 2017YFE0103100，预防 肥胖和Ⅱ型糖尿病的功能性海洋来源多糖研究，2018-01 至 2020-12，结题，参与

1. Jianwei Chen*, Wei Wang, Xubin Hu, Xingyue Lu, Chenjie Wang, Bin Wei, Huawei Zhang, Hong Wang*.Medium-sized peptides from microbial sources with potential for antibacterial drug development.Natural Product Reports. 2024. https://doi.org/10.1039/d4np00002a

2. Jianwei Chen*, Yuqi Guo, Qihao Wu, Wei wang, Jiangwei Pan, Minhong Chen, Hong Jiang, Qunjian Yin, Gaiyun Zhang, Bin Wei, Huawei Zhang, Hong Wang. Discovery of new siderophores from a marine Streptomycetes sp. via combined metabolomics and analysis of iron-chelating activity.Journal of Agricultural and Food Chemistry. 2023, 71, 17: 6584-6593.

3. Yuqi Gguo, Youmin Ying, Qihao Wu, Bin Wei, Jianwei Chen*, Hong Wang*. β -Cyclopiazonic acid binds iron demonstrating siderophore-like activity and promotes growth in Pseudomonas aeruginosa*. Journal of Oceanology and Limnology. 2023, 41, 1159-1167.

4. Zhang Junmin, Liu Pei, Chen Jianwei (共一）, Yao Dahong, Liu Qing, Zhang Juanhong, Zhang Huawei, Leung Lai-Han Elaine, Yao Xiaojun, Liu Liang*. Upgrade of chrysomycin A as a novel topoisomerase II inhibitor to curb KRAS-mutant lung adenocarcinoma progression. Pharmacological Research. 2022, 187:106565.

5. Chen Jianwei, Lu Yaojia, Ye Fei, Zhang Hongfang, Zhou Yonglie, Li Jiangtao, Wu Qiang, Xu Xuewei, Wu Qihao, Wei Bin, Zhang Huawei, Wang Hong*. A small-molecule inhibitor of the anthranilyl-CoA synthetase PqsA for  the treatment of multidrug-resistant Pseudomonas aeruginosa. Microbiology Spectrum. 2022,10(4): e02764-21.

6. Chen Jianwei, Li Yasheng, Wang Siqi, Zhang Hongfang, Du Yujie, Wu Qiang*, Wang Hong*. Targeting Clostridioides difficile: New uses for old drugs. Drug Discovery Today. 2022, 27(2): 1862-1873.

7. Chen Jianwei, Zhang Hongfang, Wang Siqi, Du Yujie, Wei Bin, Wu Qiang*, Wang Hong*. Inhibitors of bacterial extracellular vescicles. Frontiers in Microbiology. 2022. 13: 835058. 

8. Chen Jianwei, Chen Jun, Wang Siqi, Bao Xiaoze, Li Songwei, Wei Bin,  Zhang Huawei, Wang Hong*. Amycolachromones A-F, isolated from a Streptomycin-resistant strain of the deep-sea marine Actinomycete Amycolatopsis sp. WP1.Marine Drugs. 2022. 20: 162.

9. Chen Jianwei, Lu Yaojia, Du Yujie, Wang Hong*, Wuqiang*. Recent development of small-molecular inhibitors against Clostridioides difficile infection. Bioorganic Chemistry. 2022. 125: 105843.

10. Jianwei Chen, Siqi Wang, Yiming Xu, Huawei Zhang, Hong Wang*, Anti-Tyrosinase compounds from the deep-sea-derived Actinomycete Georgenia sp. 40DY180. Chemistry & Biodiversity. 2022,19: e202200037.

11. Li Yasheng#, Mao Shen#, Zhao Dongsheng#, Wang Cancan, Zu Dan, Yang Xi, Liu Guijun, Wang Sijia, Zhang Bo, Bao Xiaoze, Ye Xinyi, Wei Bin, Cui Zining*, Chen Jianwei*, Wang Hong*. Rational design of phenyl thiophene (pyridine) derivatives that overcome P-glycoprotein mediated MDR in MCF-7/ADR cell.  Bioorganic Chemistry, 2021, 114, 105075.

12. Chen Jianwei, Lu Yaojia, Ye Xinyi, Emam Mahmoud, Zhang Huawei, Wang Hong*. Current advances in Vibrio harveyi quorum sensing as drug discovery targets. European Journal of Medicinal Chemistry. 2020, 207, 112741.

13. Chen Jianwei, Zhang Panqiao, Ye Xinyi, Wei Bin, Emam Mahmoud, Zhang Huawei, Wang Hong*. The structural diversity of marine microbial secondary metabolites based on co-culture strategy: 2009-2019. Marine Drugs, 2020, 18(9), 449.

14. Chen Jianwei, Wang Bixia, Lu Yaojia, Guo Yuqi, Sun Jiadong, Wei Bin, Zhang Huawei, Wang Hong*. Quorum sensing inhibitors frommarine microorganisms and their synthetic derivatives. Marine Drugs, 2019, 17(2), 80-107.

15. Chen Jianwei, Guo Yuqi, Lu Yaojia, Wang Bixia, Sun Jiadong, Zhang Huawei, Wang Hong*. Chemistry and biology of siderophores from marine microbes. Marine Drugs, 2019, 17 (10), 562-590.

16. Jianwei Chen, Qihao Wu, Yi Hua, Jun Chen, Huawei Zhang, Hong Wang.  Potential applications of biosurfactant rhamnolipids in agriculture and  biomedicine, Applied Microbiology and Biotechnology, 2017, 101(23-24):  8309-8319.

17. Jianwei Chen, Jiadong Sun, Robert W. Deering, Nicholas DaSilva, Navindra P. Seeram, Hong Wang, David C. Rowley. Rhizoleucinoside, a rhamnolipid−amino alcohol hybrid from the rhizobial symbiont Bradyrhizobium sp. BTAi1. Organic Letters, 2016, 18(6): 1490-1493.
18. RobertW. Deering＃, Chen Jianwei＃, Sun Jiadong, Ma Hang, Javier Dubert, Juan L.Barja, Navindra P. Seeram, Wang Hong, David C. Rowley*. N‑AcylDehydrotyrosines, tyrosinase inhibitors from the marine bacterium Thalassotalea sp. PP2-459. Journal of Natural Products, 2016, 79 (2), 447-450.